This article is more than 5 years old. Information may no longer be current.

European patent awarded for Sjögren’s syndrome drug candidate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

OphthaliX recently announced that its parent company, Can-Fite BioPharma, has been granted a patent by the European Patent Office for its drug candidate CF101 for treatment of Sjögren’s syndrome in Europe until 2025.

The A3 adenosine receptor agonist is a novel small molecule, orally bioavailable drug that displayed efficacy and safety during phase 2 clinical studies, according to a press release.

CF101 currently is being developed by OphthaliX for ophthalmic indications, including dry eye syndrome (phase 3 trial), glaucoma (phase 2) and uveitis (initiating phase 2), the release said. Dry eyes and mouth are common symptoms of Sjögren’s syndrome.

Can-Fite also is developing CF101 for treating rheumatoid arthritis (phase 2b), psoriasis (phase 2/3) and other autoimmune inflammatory diseases.

The patent is pursuant to a license agreement between Can-Fite and EyeFite, its wholly owned subsidiary.